Fuqua J M, Igo S R, Hibbs C W, Poirier V L, Chambers J A, Clay W C, McGee M G, Turner S A, Norman J C
J Thorac Cardiovasc Surg. 1981 May;81(5):718-26.
A long-term, totally implantable, electrically actuated, abdominally positioned left ventricular assist system (ALVAS) is being developed, characterized in vitro, and evaluated in vivo for utilization in patients with end-stage cardiac failure refractory to conventional therapeutic techniques. The first two major subsystems of the ALVAS (the pusher-plate blood pump and electrical-mechanical energy converters) have been integrated and are undergoing in vitro characterization and long-term in vivo evaluations in calves. Duration of these studies has exceeded 6 months. System performance in terms of hemodynamic effectiveness, mechanical reliability, and biocompatibility has been excellent and no untoward effects have been observed. Long-term effectiveness of the ALVAS remains to be established in continuing experiments, with a 2 year period of clinical use as an ultimate goal.
一种长期、完全可植入、电动驱动、置于腹部的左心室辅助系统(ALVAS)正在研发中,已进行体外特性表征,并在体内进行评估,用于常规治疗技术难治的终末期心力衰竭患者。ALVAS的前两个主要子系统(推板血泵和机电能量转换器)已集成在一起,正在进行体外特性表征和在小牛体内的长期评估。这些研究的持续时间已超过6个月。在血液动力学有效性、机械可靠性和生物相容性方面,系统性能极佳,未观察到不良影响。ALVAS的长期有效性仍有待在持续实验中确定,最终目标是实现2年的临床应用。